A number of other research analysts have also issued reports on ZIMV. Credit Suisse Group started coverage on ZimVie in a report on Tuesday, March 1st. They issued an underperform rating and a $34.00 target price for the company. Guggenheim began coverage on ZimVie in a research note on Friday, March 18th. They issued a neutral rating on the stock.
NASDAQ:ZIMV opened at $18.08 on Friday. The company has a fifty day moving average of $22.91. ZimVie has a 12-month low of $17.53 and a 12-month high of $50.40. The company has a quick ratio of 1.41, a current ratio of 2.50 and a debt-to-equity ratio of 0.72.
About ZimVie (Get Rating)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- Dividend Stocks and Your Roth IRA
- The Analysts Upgrade… Retail Stocks?
- The Q2 Earnings Season Could Be A Bloodbath
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.